Core Alzheimer's disease biomarkers in cerebrospinal fluid (CSF) show varying agreement with amyloid-PET imaging, necessitating a detailed analysis across multiple sites.
The study involved 236 participants, primarily diagnosed with Alzheimer's-related conditions, demonstrating an overall percent agreement (OPA) of 73%-75% for individual CSF biomarkers compared to amyloid-PET, but improved to 82%-88% with combined biomarker ratios.
Overall, cases showing presence of all three biomarkers (Aβ, T, and N) had the highest agreement with amyloid-PET results, indicating that using combined CSF biomarkers is more effective for predicting amyloid presence than single biomarkers alone.